| |
[摘要]：Atacicept (TACI-Ig, TACE-Fc5) is a soluble recombinant fusion protein containing the extracellular BAFF/APRIL-binding domain of the TACI receptor and the Fe region of human IgG that blocks both BAFF and APRIL, two members of the tumor necrosis factor (TNF) superfamily known to play key roles in B-cell activation. BAFF and APRIL are upregulated in B-cell malignancies and autoimmune diseases, and blocking their activity via atacicept may prove to be a potential therapeutic approach. Preclinical studies have demonstrated the ability of atacicept to suppress the production of autoreactive antibodies and inhibit the development of mature spleen B cells by arresting the transition of immature B cells from the T1 to the T2 stage. Atacicept was also shown to inhibit disease progression in mouse models of rheumatoid arthritis and systemic lupus erythematosus (SLE). Preliminary data from clinical studies support the biological activity, tolerability and safety of S.C. atacicept administration. Atacicept is currently undergoing phase II/III clinical trials for the treatment of autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, SLE amd optic neuritis, as well as phase I trials for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma. |
|
